



US 20150254397A1

(19) **United States**(12) **Patent Application Publication**
ROGAN et al.(10) **Pub. No.: US 2015/0254397 A1**(43) **Pub. Date: Sep. 10, 2015**(54) **METHOD OF VALIDATING MRNA SPLCIING
MUTATIONS IN COMPLETE
TRANSCRIPTOMES****Publication Classification**(71) Applicant: **Cytogenomix Inc**, London (CA)(72) Inventors: **PETER KEITH ROGAN**, LONDON
(CA); **STEPHANIE NICOLE
DORMAN**, LONDON (CA); **COBY
VINER**, LONDON (CA); **ELISEOS
JOHN MUCAKI**, LONDON (CA)(51) **Int. Cl.****G06F 19/18** (2006.01)**C40B 30/02** (2006.01)**C12Q 1/68** (2006.01)(52) **U.S. Cl.**CPC **G06F 19/18** (2013.01); **C12Q 1/6883**
(2013.01); **C40B 30/02** (2013.01); **C12Q**
2600/16 (2013.01); **C12Q 2600/156** (2013.01);
C12Q 2600/118 (2013.01)(73) Assignee: **Cytogenomix Inc**, London (CA)(21) Appl. No.: **14/594,109**(22) Filed: **Jan. 10, 2015****Related U.S. Application Data**(60) Provisional application No. 61/926,312, filed on Jan.
11, 2014, provisional application No. 62/044,403,
filed on Sep. 1, 2014.

(57)

ABSTRACT

A method is described for the automatic validation of DNA sequencing variants that alter mRNA splicing from nucleic acids isolated from a patient or tissue sample. Evidence the a predicted splicing mutation is demonstrated by performing statistically valid comparisons between sequence read counts of abnormal RNA species in mutant versus non-mutant tissues. The method leverages large numbers of control samples to corroborate the consequences of predicted splicing variants in complete genomes and exomes for individuals carrying such mutations. Because the method examines all transcript evidence in a genome, it is not necessary a priori to know which gene or genes carry a splicing mutation.